<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01160120</url>
  </required_header>
  <id_info>
    <org_study_id>HIV-NAT 118</org_study_id>
    <nct_id>NCT01160120</nct_id>
  </id_info>
  <brief_title>Therapeutic Drug Monitoring (TDM) in Generic Tenofovir/Lamivudine/Efavirenz</brief_title>
  <official_title>Generic Fixed Dose Combination (FDC) of Tenofovir(TDF) /Lamivudine(3TC)/Efavirenz (EFV) Tablets 300/300/600 mg</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The HIV Netherlands Australia Thailand Research Collaboration</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mylan Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The HIV Netherlands Australia Thailand Research Collaboration</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the mid levels of the tenofovir, lamivudine, and
      efavirenz, and 144 weeks safety and efficacy of the generic fixed dose combination of
      tenofovir /lamivudine/efavirenz tablets 300/300/600 mg in Thai HIV-infected patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial drug FDC of TDF/3TC/EFV is a new formulation combining fixed doses of the
      nucleoside reverse transcriptase inhibitors lamivudine 300 mg and tenofovir disoproxil
      fumarate 300 mg with the non nucleoside reverse transcriptase inhibitor efavirenz 600 mg for
      once daily and one-tablet HAART. Co-formulated TDF/3TC/EFV demonstrated bioequivalent to
      original individual EFV 3TC and TDF in Indian healthy volunteers (unpublished data). It has
      not been evaluated in clinical trials.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mid levels of TDF, 3TC, and EFV between brand and generic</measure>
    <time_frame>144 weeks</time_frame>
    <description>mid levels of TDF, 3TC, and EFV between brand and generic</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>kidney, liver, CD4 and viral load overtime</measure>
    <time_frame>144 weeks</time_frame>
    <description>kidney, liver, CD4 and viral load overtime</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients can be either treatment-naïve or treatment-experienced when entering this clinical trial. After meeting the inclusion and exclusion criteria, patients will start with generic FDC of TDF/3TC/EFV 1 pill a day at night time. Only patient who are on individual TDF 3TC and EFV will undergo TDM sampling ( 11-13 hours after dosing) at baseline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>generic FDC of TDF/3TC/EFV</intervention_name>
    <description>Patients who were on individual TDF 3TC and EFV regimen before baseline will undergo TDM at baseline. Therapeutic drug monitoring (TDM) of generic FDC of TDF/3TC/EFV will be done after 4 weeks, to ensure steady state. At baseline and week 4 safety data will be obtained. In order to assess the efficacy and the long term safety of this drug, at week 12, 24 and 48 viral load, CD4 and safety parameters will be obtained.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  Evidence of HIV infection

          -  Age&gt; 18 years

          -  On a TDF/3TC/EFV (separated pills) containing HAART regimen with a VL &lt; 50 copies
             within 24 weeks or ARV naïve

          -  eGFR &gt;70 cc/min

          -  Currently having no AIDS defining illness

          -  No history of NRTI/NNRTI/PI failure

          -  Willing to adhere to the protocol requirements

        Exclusion Criteria:

          -  Any history of taking CYP450 inhibitors or inducers drugs within 14 days of enrollment
             in the study

          -  Current pregnancy or lactating or plan to be pregnant

          -  Active opportunistic infection

          -  ALT more than 2 x upper limit

          -  Creatinine more than 1.5 time the upper limit

          -  Active drug abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anchalee Avihingsanon, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The HIV Netherlands Australia Thailand Research Collaboration</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HIV-NAT</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <link>
    <url>http://www.hivnat.org</url>
    <description>HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT)</description>
  </link>
  <results_reference>
    <citation>Avihingsanon A, Sophonphan J, Thammajaruk N, Chaihong P, Burger D, Cressey TR, Ramautarsing RA, Praditornsilpa K, Avihingsanon Y, Ruxrungtham K and HIV-NAT 114 study team. Plasma Tenofovir Concentrations and Proximal Tubular Dysfunction in HIV-Infected Adults Receiving Tenofovir in Thailand. AIDS Clin Res 2015, 6:7 Doi: http://dx.doi.org/10.4172/2155-6113.1000477</citation>
  </results_reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2010</study_first_submitted>
  <study_first_submitted_qc>July 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2010</study_first_posted>
  <last_update_submitted>February 18, 2016</last_update_submitted>
  <last_update_submitted_qc>February 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>fixed dose combinations</keyword>
  <keyword>tenofovir</keyword>
  <keyword>lamivudine</keyword>
  <keyword>efavirenz</keyword>
  <keyword>therapeutic drug levels</keyword>
  <keyword>safety and efficacy</keyword>
  <keyword>HIV</keyword>
  <keyword>To evaluation new formulations of FDC of TDF/3TC/EFV</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

